levofloxacin / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   137 Trials   137 Trials   5343 News 


12345678910111213...9091»
  • ||||||||||  Krazati (adagrasib) / BMS, avutometinib (VS-6766) / Verastem
    Acute Interstitial Nephritis and Acute Tubular Injury Associated with Novel Drugs for Non-Small Cell Lung Cancer: Avutometinib and Adagrasib () -  Mar 13, 2025 - Abstract #NKFSCM2025NKF_SCM_612;    
    A kidney biopsy on 9/20/2024 showed moderate AIN, ATI, and mild fibrosis. Ultrastructural studies revealed myelin-like inclusions in podocytes, mesangial areas, and the cytoplasm of tubular cells, likely related to the new therapy.Results Avutometinib and Adagrasib were withheld, and the patient was treated with corticosteroids, resulting in improvement of kidney function to baseline.Conclusion This is the first case report of AKI due to AIN and ATI following the use of Avutometinib and Adagrasib for NSCLC, highlighting their potential renal side effects.
  • ||||||||||  Journal:  Machine learning to predict urine culture antibiotic sensitivities in the emergency department. (Pubmed Central) -  Mar 12, 2025   
    Countries should stay vigilant for prevalence increases in S. pneumoniae serotype 23B, given the decreased susceptibility to penicillin and co-trimoxazole of the 23B1 variant. We predicted urine cultures to be sensitive vs intermediate or resistant with area under the receiver operating curve (AUROC) values ranging from 70
  • ||||||||||  levofloxacin / Generic mfg., Gatiflox (gatifloxacin) / Orient Europharma, moxifloxacin intravenous / Generic mfg.
    Journal:  Machine learning-assisted ratiometric fluorescence sensor array for recognition of multiple quinolones antibiotics. (Pubmed Central) -  Mar 12, 2025   
    The performance of the DT model is evaluated using accuracy, precision, recall, and F1 score, with stability and generalizability confirmed by stratified ten-fold cross-validation. This approach demonstrates high sensitivity, selectivity and applicability and provides an effective solution for antibiotic residue detection.
  • ||||||||||  Journal:  Positive Murphy's Sign of Fitz-Hugh-Curtis Syndrome. (Pubmed Central) -  Mar 10, 2025   
    Without a definitive diagnosis, she was prescribed acetaminophen and levofloxacin and discharged...The patient was diagnosed with pelvic inflammatory disease, specifically Fitz-Hugh-Curtis syndrome (FHCS), and treated with ceftriaxone and minocycline...This case highlights the need for careful clinical evaluation and consideration of FHCS in patients presenting with right upper quadrant pain, especially when laboratory findings and imaging studies do not support biliary disease. A thorough history including symptoms of pelvic inflammatory disease, such as lower abdominal pain and vaginal discharge, is also necessary to accurately diagnose FHCS.
  • ||||||||||  levofloxacin / Generic mfg.
    Journal:  Skin-Inspired and Self-Regulated Hydrophobic Hydrogel for Diabetic Wound Therapy. (Pubmed Central) -  Mar 10, 2025   
    Inspired by the structure and function of the skin, we herein delicately design a novel swollen hydrophobic hydrogel (QL@MAB) composed of hydrophobic methyl acrylate (MA) and (3-acrylamidophenyl)boronic acid (AAPBA) network and co-loaded with antioxidant quercetin (Q) and antibiotic levofloxacin (L) for efficient diabetic wound therapy...In the infected diabetic rats, QL@MAB achieves rapid wound debridement and re-epithelization while promoting angiogenesis, hair follicle regeneration, and extracellular matrix remodeling. Taken together, this study not only represents a multipronged dressing for effective interventions of diabetic wounds but also contributes to the rational design of smart hydrogels tailored for biomedical applications.
  • ||||||||||  Sirturo (bedaquiline) / J&J, Pharmstandard
    Trial completion date, Trial initiation date, Trial primary completion date:  BREACH-TB: Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB (clinicaltrials.gov) -  Mar 6, 2025   
    P3,  N=2530, Not yet recruiting, 
    The results indicate that genotype testing of H. pylori can serve as a method for predicting its resistance to clarithromycin and levofloxacin. Trial completion date: Nov 2027 --> Nov 2030 | Initiation date: Mar 2025 --> Dec 2025 | Trial primary completion date: Nov 2027 --> Nov 2029
  • ||||||||||  levofloxacin / Generic mfg.
    Biomarker, Journal, Next-generation sequencing:  Resistome and virulome determination in Helicobacter pylori using next-generation sequencing with target-enrichment technology. (Pubmed Central) -  Mar 5, 2025   
    Mutations in the 23S rDNA sequence associated with macrolide resistance and in the quinolone resistance-determining region of gyrase A associated with levofloxacin resistance were correctly identified...The significance of our research is the development of a novel next-generation sequencing strategy based on target-enrichment. This approach enables the identification of the resistome and the virulome of H. pylori directly from gastric biopsies, providing clinicians with a broad overview of therapeutic options.
  • ||||||||||  levofloxacin / Generic mfg., tetracycline / Generic mfg., amoxicillin / Generic mfg.
    Journal:  Molecular Epidemiology and Antibiotic Resistance Profiling of Staphylococcus aureus Isolates from Camel Mastitis. (Pubmed Central) -  Mar 1, 2025   
    Identified risk factors provide valuable insights into management practices that contribute to disease occurrence, aiding in the development of targeted control strategies. Additionally, antimicrobial susceptibility findings offer guidance for optimizing treatment protocols to effectively manage S. aureus-induced mastitis in camels and mitigate the spread of antimicrobial resistance.
  • ||||||||||  levofloxacin / Generic mfg.
    Clinical, Retrospective data, Review, Journal:  Effectiveness and safety of levofloxacin in the treatment of community-acquired pneumonia: A systematic review and meta analysis. (Pubmed Central) -  Feb 27, 2025   
    The literature was evaluated to have a low risk level and a high reference value. The results of meta analysis showed that there was no significant difference in the clinical cure rate, microbiologic (bacteriologic) success rate, adverse event rate and mortality rate between the study group and the control group (P>0.05).As a result of the study, it was concluded that: levofloxacin has significant efficacy and safety in the treatment of CAP, and other antimicrobial drugs (e.g., moxifloxacin) have comparable efficacy and higher safety than levofloxacin, which provides a more diversified solution for the treatment of CAP.
  • ||||||||||  Lamprene (clofazimine) / Novartis
    Journal:  GrcC1 mediates low-level resistance to multiple drugs in M. marinum, M. abscessus, and M. smegmatis. (Pubmed Central) -  Feb 26, 2025   
    These findings represent the first connection between GrcC1 and drug resistance, offering new insights into combating infections caused by nontuberculous mycobacteria (NTM). Our work highlights the potential of GrcC1 as a target for novel therapeutic approaches and as a diagnostic marker for drug-resistant NTM infections.
  • ||||||||||  levofloxacin / Generic mfg.
    PK/PD data, Preclinical, Journal:  Pharmacokinetics of Levofloxacin Entrapped in Non-Ionic Surfactant Vesicles (Niosomes) in Sprague Dawley Rats. (Pubmed Central) -  Feb 26, 2025   
    Thus, formulation in niosomes altered levofloxacin biodistribution by concentrating the drug in the vascular compartment. Niosome encapsulation of levofloxacin altered its biodistribution and pharmacokinetic profile, possibly by protecting i.p. levofloxacin en route into plasma, and significantly enhanced its plasma concentration with enhanced potential for treating intravascular infections.
  • ||||||||||  ciprofloxacin oral / Generic mfg., levofloxacin / Generic mfg.
    Review, Journal:  Fluoroquinolone-Mediated Tendinopathy and Tendon Rupture. (Pubmed Central) -  Feb 26, 2025   
    Specifically, follow-up studies should focus on understanding the FQ-mediated tendon changes in a more complex manner and integrating in vitro with in vivo models. With respect to in vitro systems, the field should move towards three-dimensional models that reflect the cellular diversity found in the tissue.
  • ||||||||||  Journal:  Clinical Features and Antibiotic Susceptibility of Staphylococcus aureus-Infected Dermatoses. (Pubmed Central) -  Feb 26, 2025   
    Other pathogens, including Pseudomonas aeruginosa and Escherichia coli, were isolated in 27.9% of cases. This study highlights the high prevalence of MRSA in outpatient dermatology settings, emphasizing the need for local antimicrobial resistance surveillance to guide treatment strategies and improve outcomes in superinfected dermatoses.
  • ||||||||||  Journal:  Agar-Dilution Is Comparable to Broth Dilution for MIC Determination in Streptococcus agalactiae. (Pubmed Central) -  Feb 26, 2025   
    Agar-dilution is a valid method for high-throughput AMR surveillance of retrospective cohorts (96 isolates per plate) and is critical for identifying emerging GBS resistance trends and informing therapeutic guidelines. However, due to the large number of plates required per antimicrobial, it is impractical for routine clinical diagnostics.